|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effect of vildagliptin as add-on therapy to a low-dose metformin显示文摘AIM:To evaluate the efficacy and safety of the addition of vildagliptin to low-dose metformin and compare it to an uptitration of metformin in type 2 diabetes mellitus(T2DM) patients who have inadequate control with metformin monotherapy.METHODS:Eligible patients were randomized to receive vildagliptin 100 mg qd or metformin(500 mg qd for 2 wk and then 500 mg bid) added to open label me tformin 500 mg bid for the 24 wk.The primary endpoi nt was baseline to endpoint hemoglobin A1c(HbA1c) change.RESULTS:The adjusted mean change from baseline in HbA1c at the 24th wk was-0.51% in the vildagliptin/metformin group(mean baseline HbA1c:7.4%) and-0.37% in the metformin monothera py group(mean baseline HbA1c:7.3%).The mean diffe rence was-0.14% with 95% Confidence Interval(-0.24%,-0.05%).As non-inf e riority(margin of 0.4%) was achieved,a test for superiority was performed.This test showed statistically significant superiority of the combination over monotherapy group(P = 0.002).Gastrointestinal(GI) adverse events were signif icantly more frequent in the metformin group than the combin ation group(21.0% vs 15.4%,P = 0.032).CONCLUSION:In patients with T2DM inadequately controlled with metformin up to 1000 mg daily,the addition of vildagliptin 100 mg daily achieved larger HbA1c reduction with fewer GI events than with increa sing the metformin dose. | Claudia Filozof Sherwyn Schwartz James E Foley | 2010 | World Journal of Diabetes2010，1，1： | 8 |
| 2 | Assessment of stable coronary artery disease by cardiovascular magnetic resonance imaging: Current and emerging techniques显示文摘Coronary artery disease(CAD) is a leading cause of death and disability worldwide. Cardiovascular magnetic resonance(CMR) is established in clinical practice guidelines with a growing evidence base supporting its use to aid the diagnosis and management of patients with suspected or established CAD. CMR is a multi-parametric imaging modality that yields high spatial resolution images that can be acquired in any plane for the assessment of global and regional cardiac function, myocardial perfusion and viability, tissue characterisation and coronary artery anatomy, all within a single study protocol and without exposure to ionising radiation. Advances in technology and acquisition techniques continue to progress the utility of CMR across a wide spectrum of cardiovascular disease, and the publication of large scale clinical trials continues to strengthen the role of CMR in daily cardiology practice. This article aims to review current practice and explore the future directions of multi-parametric CMR imaging in the investigation of stable CAD. | James RJ Foley Sven Plein John P Greenwood | 2017 | World Journal of Cardiology2017，9，2： | 6 |
| 3 | Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes显示文摘AIM: To assess the efficacy and safety of vildagliptin 50 mg bid as add-on therapy to insulin in Asian patients with type 2 diabetes mellitus(T2DM).METHODS: This was a post hoc analysis of a subgroup of Asian patients from a multicenter,randomized,double-blind,placebo-controlled,parallel-group study in T2DM patients inadequately controlled by stable insulin therapy,with or without metformin.A total of 173 patients were randomized 1:1 to receive treatment with vildagliptin 50 mg bid(n = 87) or placebo(n = 86) for 24 wk.Changes in HbA1c and fasting plasma glucose(FPG),from baseline to study endpoint,were analyzed using an analysis of covariance model.Change from baseline to endpoint in body weight was summarized by treatment.Safety and tolerability of vildagliptin was also evaluated.RESULTS: After 24 wk,the difference in adjusted mean change in HbA1c between vildagliptin and placebo was 0.82%(8.96 mmol/mol;P < 0.001) in Asian subgroup,0.85%(9.29 mmol/mol;P < 0.001) in patients also receiving metformin,and 0.73%(7.98 mmol/mol;P < 0.001) in patients without metformin,all in favor of vildagliptin.There was no significant difference in the change in FPG between treatments.Weight was stable in both treatment groups(+0.3 kg and-0.2 kg,for vildagliptin and placebo,respectively).Overall,vildagliptin was safe and well tolerated with similarly low incidences of hypoglycemia(8.0% vs 8.1%) and no severe hypoglycemic events were experienced in either group.CONCLUSION: In Asian patients inadequately controlled with insulin(with or without concomitant metformin),insulin-vildagliptin combination treatment significantly reduced HbA1c compared with placebo,without an increase in risk of hypoglycemia or weight gain. | Plamen Kozlovski James Foley Qing Shao Valentina Lukashevich Wolfgang Kothny | 2013 | World Journal of Diabetes2013，4，4： | 6 |
| 4 | Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience显示文摘 | James Foley | 2010 | Vascular Health and Risk Management (default)2010，，： | 3 |
| 5 | Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes显示文摘 | Bo Ahrén Anja Schweizer Sylvie Dejager Beth E. Dunning Peter M. Nilsson Margaretha Persson James E. Foley | 2009 | The Journal of Clinical Endocrinology & Metabolism2009，，4： | 3 |
| 6 | Minimally Invasive Lumbar Fusion显示文摘 | Kevin T. Foley Langston T. Holly James D. Schwender | 2003 | Spine (S Suppl)2003，，15： | 2 |
| 7 | The Incidence, Management, and Complications of Dysphagia in Patients with Medullary Strokes Admitted to a Rehabilitation Unit显示文摘 | Robert Teasell Norine Foley James Fisher Hillel Finestone | 2002 | Dysphagia2002，，2： | 1 |
| 8 | Knowing when to grow: signals regulating bud dormancy显示文摘 | David P. Horvath James V. Anderson Wun S. Chao Michael E. Foley | 2003 | Trends in Plant Science2003，，11： | 1 |
| 9 | Foreign Direct Investment in a World of Multiple Taxes 显示文摘 | Desai Mihir A C Fritz Foley James R Hines Jr | 2004 | Journal of Public Economics December2004，88，12： | 1 |
| 10 | Minimally Invasive Lumbar Fusion显示文摘 | Kevin T. Foley Langston T. Holly James D. Schwender | 2003 | Spine . 2003 (15S)2003，，15： | 1 |
| 11 | Image-Guided High-Intensity Focused Ultrasound for Conduction Block of Peripheral Nerves显示文摘 | Jessica L. Foley James W. Little Shahram Vaezy Ph.D | 2007 | Annals of Biomedical Engineering2007，，1： | 1 |
| 12 | Cultural representations of thinness in women, redux: Playboy magazine’s depiction of beauty from 1979 to 1999显示文摘 | Mia Foley Sypeck James J. Gray Sarah F. Etu Anthony H. Ahrens James E. Mosimann Claire V. Wiseman | 2006 | Body Image2006，，3： | 1 |
| 13 | Clinical evidence and mechanistic basis for vildagliptin’s effect in combination with insulin显示文摘 | Anja Schweizer Bo Ahren Wolfgang Kothny James Foley | 2013 | Vascular Health and Risk Management (default)2013，，： | 1 |
| 14 | A Multinational Perspective on Capital Structure Choice and Internal Capital Markets显示文摘 | MIHIR A. DESAI C. FRITZ FOLEY JAMES R. HINES | 2004 | The Journal of Finance2004，，6： | 1 |
| 15 | The Dipeptidyl Peptidase IV Inhibitor Vildagliptin Suppresses Endogenous Glucose Production and Enhances Islet Function after Single-Dose Administration in Type 2 Diabetic Patients显示文摘 | Bogdan Balas Muhammad R. Baig Catherine Watson Beth E. Dunning Monica Ligueros-Saylan Yibin Wang Yan-Ling He Celia Darland Jens J. Holst Carolyn F. Deacon Kenneth Cusi Andrea Mari James E. Foley Ralph A. DeFronzo | 2007 | The Journal of Clinical Endocrinology & Metabolism2007，，4： | 1 |
| 16 | The incidence, management, and complications of dysphagia in patients with medullary strokes admitted to a rehabilitation unit显示文摘 | Robert Teasell Norine Foley James Fisher Hillel Fine- stone | 2014 | Dysphagia2014，13，2： | 1 |
| 17 | Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes显示文摘 | Irfan Vardarli Michael A. Nauck Lars D. K?the Carolyn F. Deacon Jens J. Holst Anja Schweizer James E. Foley | 2011 | The Journal of Clinical Endocrinology & Metabolism2011，，4： | 1 |
| 18 | The Incidence, Management, and Complications of Dysphagia in Patients with Medullary Strokes Admitted to a Rehabilitation Unit显示文摘 | Robert Teasell Norine Foley James Fisher Hillel Finestone | 2002 | Dysphagia2002，，2： | 1 |
| 19 | A Patient with Primary Biliary Cirrhosis and Elevated LDL Cholesterol/Commentary显示文摘 | Foley Kevin F Silveira Marina G Hornseth Jean M Lindor Keith D McConnell Joseph P Otvos James | 2009 | Clinical Chemistry2009，，1： | 1 |
| 20 | Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT显示文摘 | Yan-Ling He Yibin Wang Julie M. Bullock Carolyn F. Deacon Jens Juul Holst Beth E. Dunning Monica Ligueros-Saylan James E. Foley | 2007 | The Journal of Clinical Pharmacology2007，，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员